Advertisement
Advertisement

Contact Person

Laura Lenz

Advertising Manager

Phone: +49 (0)711 - 2 29 87 58
Fax: +49 (0)711 - 2 29 87 50
Opens window for sending emailsend an Email


Sponsored Content

Thrombosis and Haemostasis has a long history of working with our partners in producing and distributing their content, such as symposium or congress proceedings, to a larger and more targeted audience. This content is distributed alongside our standard journal content as a loose insert, or it is printed directly within the journal itself.

If you are interested in producing your special content with the journal of Thrombosis and Haemostasis, you can find out more information here, or by contacting Laura Lenz at Öffnet ein Fenster zum Versenden der E-MailLaura.Lenz(at)schattauer.de.

For all content which is currently available for downloading, please see directly below. A listing of all sponsored content then follows that.


Supplement Issues

  • Supplement 1/2011 - European Platelet Academy: Contemporary issues in atherothrombosis
    This supplement was supported by an unrestricted grant to the University of Sheffield, UK, from Eli Lilly and Daiichi Sankyo in support of the European Platelet Academy.
    Published alongside the regular June 2011 issue of Thrombosis and Haemostasis
    View Issue


CSL Behring Newsletters

  • Innovations in coagulation: improved options for treatment of hemophilia A and B
    News from the XXX International Congress of the World Federation of Hemophilia (WFH) in Paris, France, and based on a CSL Behring Symposium.
    Sponsored by CSL Behring GmbH, Marburg, Germany.
    Printed in the January 2013 issue of Thrombosis and Haemostasis.
    Opens external link in new windowDownload

  • Congenital and acquired bleeding disorders: the right factor for the right patient
    News from the XXX International Congress of the World Federation of Hemophilia (WFH) in Paris, France, and based on CSL Behring Symposium.
    Sponsored by CSL Behring GmbH, Marburg, Germany.
    Printed in the December 2012 issue of Thrombosis and Haemostasis.

  • CSL Behring – Prof. Heimburger Award 2012 recognizes innovative coagulation research by young investigators
    News from the CSL Behring – Prof. Heimburger Award 2012 Symposium in Marburg, Germany which took place on April 27th, 2012.
    Sponsored by CSL Behring GmbH, Marburg, Germany.
    Printed in the September 2012 issue of Thrombosis and Haemostasis.

  • Factors for Life® - advances in the treatment of congenital and coagulopathic bleeding disorders
    News from the XXIII Congress of the ISTH in Kyoto, Japan, based on the CSL Behring symposium which took place on July 24th, 2011.
    Sponsored by CSL Behring GmbH, Marburg, Germany.
    Printed in the February 2012 issue of Thrombosis and Haemostasis.

  • CSL Behring – Challenges and innovations in the treatment of bleeding disorders.
    News from the Hemophilia 2010 World Congress in Buenos Aires, Argentina. Text is based upon CSL Behring symposium which occurred on July 13th, 2010.
    Sponsored by CSL Behring, Marburg, Germany.
    Printed in the November 2010 issue of Thrombosis and Haemostasis.


Loose inserts

  • Effective practical management of patients with thromboembolic disorders using rivaroxaban.
    Content based on a symposium which took place at the 58th Annual Meeting of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis on June 28th.
    Symposium as well as this insert were sponsored by Bayer HealthCare Pharmaceuticals.
    Distributed in association with the December 2012 issue of Thrombosis and Haemostasis.
    Download

  • New perspectives, new strategies in venous thromboembolic disease
    A satellite symposium at the 50th ASH Annual Meeting: December 5, 2008 in San Francisco, California, USA.
    Sponsored by an educational grant from Bayer Healthcare AG and Ortho-McNeil Inc., Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc. Administered by Ortho-McNeil Janssen Scientific Affairs, LLC.
    Distributed in association with the June 2009 issue of Thrombosis and Haemostasis.
    Download

The following is a listing of all industry sponsored content which has been published in the journal, or distributed along with it as a loose insert since 2004.

2013

  • Five years, five indications: rivaroxaban for the treatment and prevention of thromboembolism
    This supplement was sponsored by Bayer HealthCare Pharmaceuticals.
    Distributed with the October 2013 issue of Thrombosis and Haemostasis.

  • Tailored approach for von Willebrand patients who benefit from WILLFACT®
    Content based on the LFB Symposium at the 57th Annual Meeting of the GTH on February 20, 2013 in Munich, Germany.
    Symposium as well as this insert were sponsored by LFB Biomedicaments, France.
    Distributed with the September 2013 issue of Thrombosis and Haemostasis.

  • Von Willebrand disease & Hemophilia.
    Content based on LFB Symposia at the World Federation of Hemophilia Congress on July 9th, 2012, in Paris, France.
    Symposia as well as this insert were sponsored by LFB Biomedicaments, France.
    Distributed with the April 2013 issue of Thrombosis and Haemostasis.

  • Factor VIII treatment of haemophilia – Facing the development and treatment of inhibitors.
    III. Biotest European Haemophilia Forum; Naples, Italy from October 11-12, 2012.
    Sponsored by Biotest.
    Distributed in association with the February 2013 issue of Thrombosis and Haemostasis.

  • Innovations in coagulation: improved options for treatment of hemophilia A and B
    News from the XXX International Congress of the World Federation of Hemophilia (WFH) in Paris, France, and based on a CSL Behring Symposium.
    Sponsored by CSL Behring GmbH, Marburg, Germany.
    Printed in the January 2013 issue of Thrombosis and Haemostasis.
    Opens external link in new windowDownload

2012

  • Effective practical management of patients with thromboembolic disorders using rivaroxaban.
    Content based on a symposium which took place at the 58th Annual Meeting of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis on June 28th.
    Symposium as well as this insert were sponsored by Bayer HealthCare Pharmaceuticals.
    Distributed in association with the December 2012 issue of Thrombosis and Haemostasis.

  • Pioneering hemophilia research and treatment
    Content is based on the symposium, “Robert Koch Award 2012” which took place on July 7th 2012 at the World Federation of Hemophilia (WFH) Congress in Paris, France.
    This symposium, as well as this loose insert, was sponsored by Bayer HealthCare.
    Distributed with the November 2012 issue of Thrombosis and Haemostasis.

  • Congenital and acquired bleeding disorders: the right factor for the right patient
    News from the XXX International Congress of the World Federation of Hemophilia (WFH) in Paris, France, and based on CSL Behring Symposium.
    Sponsored by CSL Behring GmbH, Marburg, Germany.
    Printed in the December 2012 issue of Thrombosis and Haemostasis.

  • CSL Behring – Prof. Heimburger Award 2012 recognizes innovative coagulation research by young investigators
    News from the CSL Behring – Prof. Heimburger Award 2012 Symposium in Marburg, Germany which took place on April 27th, 2012.
    Sponsored by CSL Behring GmbH, Marburg, Germany.
    Printed in the September 2012 issue of Thrombosis and Haemostasis.

  • Factors for Life® - advances in the treatment of congenital and coagulopathic bleeding disorders
    News from the XXIII Congress of the ISTH in Kyoto, Japan, based on the CSL Behring symposium which took place on July 24th, 2011.
    Sponsored by CSL Behring GmbH, Marburg, Germany.
    Printed in the February 2012 issue of Thrombosis and Haemostasis.

2011

  • Modern treatment options for von Willebrand disease and haemophilia B – What are the benefits for the patients?
    A Symposium at the World Federation of Haemophilia Congress 2010: July 13, 2010 in Buenos Aires, Argentina.
    Sponsored by Octapharma AG, Lachen, Switzerland.
    Distributed in association with the September 2011 issue of Thrombosis and Haemostasis.

  • CSL Behring – Prof. Heimburger Award 2011 celebrates the work of talented young investigators
    News from the CSL Behring – Prof. Heimburger Award 2011 Symposium in Marburg, Germany, on April 8, 2011.
    Sponsored by CSL Behring GmbH, Marburg, Germany.
    Printed in the August 2011 issue of Thrombosis and Haemostasis.

  • VWF monotherapy in von Willebrand disease – Reliabe hemostasis
    A special symposium on new therapeutic possibilities in hemophilia and von Willebrand syndrome at the 55th Annual Meeting of the GTH; February 16, 2011 in Wiesbaden, Germany.
    Sponsored by SOBI (Swedish Orphan Biovitrum).
    Distributed with the July 2011 issue of Thrombosis and Haemostasis.

  • Supplement 1/2011 - European Platelet Academy: Contemporary issues in atherothrombosis
    This supplement was supported by an unrestricted grant to the University of Sheffield, UK, from Eli Lilly and Daiichi Sankyo in support of the European Platelet Academy.
    Published alongside the regular June 2011 issue of Thrombosis and Haemostasis
    View Issue

  • Inhibitors in haemophilia A – Prevention, current management and personalised therapy perspectives.
    Text is based on an Octapharma Symposium which occurred on July 13th, 2010, at the World Federation of Haemophilia Congress in Buenos Aires, Argentina.
    This loose insert was sponsored by Octapharma AG (Lachen, Switzerland).
    Distributed in association with the March 2011 issue of Thrombosis and Haemostasis

  • Shifting for a new paradigm in the management of von Willebrand patients.
    Text is from an LFB satellite symposium which occurred on July 12, 2010 at the World Federation of Hemophilia Congress in Argentina.
    Sponsored by LFB.
    Distributed with the January 2011 issue of Thrombosis and Haemostasis. 

2010

  • CSL Behring – Challenges and innovations in the treatment of bleeding disorders.
    News from the Hemophilia 2010 World Congress in Buenos Aires, Argentina. Text is based upon CSL Behring symposium which occurred on July 13th, 2010.
    Sponsored by CSL Behring, Marburg, Germany.
    Printed in the November 2010 issue of Thrombosis and Haemostasis.

  • CSL Behring – Prof. Heimburger Award 2010 rewards excellence in coagulation research.
    News from the CSL Behring – Prof. Heimburger Award 2010 Symposium in Marburg, Germany, on March 29, 2010.
    Sponsored by CSL Behring GmBH, Marburg, Germany.
    Printed in the September 2010 issue of Thrombosis and Haemostasis.

  • Von Willibrand disease – VWF monotherapy. Why not focus on the missing ingredient?
    A special symposium presented at the GTH 2010 congress in Nürnberg, Germany on February 26, 2010 (“WILLFACT® - purely designed to protect patients with von Willebrand disease”).
    Sponsored by LFB SA, Courtaboeuf Cedex, France.
    Distributed in association with the June 2010 issue of Thrombosis and Haemostasis.

  • From human to humans – Introducing the first recombinant human FVIII product produced from a human cell line
    A special symposium at the International Society on Thrombosis and Haemostasis (ISTH) Congress 2009: July 15, 2009, in Boston, Massachusetts, USA.
    Sponsored by Octapharma AG, Lachen, Switzerland.
    Distributed with the February issue of Thrombosis and Haemostasis.


2009

  • Prevention and eradication of FVIII inhibitors: Bridging lab and field research
    A special symposium at the International Society on Thrombosis and Haemostasis (ISTH) Congress 2009: July 12, 2009 in Boston Massachusetts, USA.
    Sponsored by Octapharma AG, Lachen, Switzerland.
    Distributed in association with the December issue of Thrombosis and Haemostasis.

  • Addressing challenges in the care of hemophilia patients with inhibitors
    A symposium at the World Federation of Hemophilia's XXVIII International Congress: June 1-5, 2008 in Istanbul, Turkey.
    Sponsored by Baxter Healthcare, USA.
    Distributed in association with the November issue of Thrombosis and Haemostasis.

  • News from the XXII Congress of the ISTH in Boston, USA. Treatment of congenital bleeding disorders: Future trends in Management
    CSL Behring Symposium “Treatment of congenital bleeding disorders: future trends in management”, July 15, 20009 in Boston, USA.
    Printed in November issue of Thrombosis and Haemostasis.

  • News from the XXII Congress of the ISTH in Boston, USA: Diagnosis and management of inherited von Willibrand disease in the next decade: a clinical perspective
    CSL Behring Symposium “Diagnosis and management of inherited von Willibrand disease in the next decade: a clinical perspective”, July 13, 2009 in Boston, USA.
    Printed in October issue of Thrombosis and Haemostasis.

  • CSL Behring Announces Winners of the 2009 Prof. Heimburger Award.
    CSL Behring, Prof. Heimburger Award symposium, May 29, 2009, Marburg, Germany.
    Printed in the September issue of Thrombosis and Haemostasis.

  • 2009 Prof. Heimburger Award Symposium in Marburg, Germany
    Prof. Heimburger Award honours the next generation of haemophilia treatment specialists

    CSL Behring, Prof. Heimburger Award symposium, May 29, 2009, Marburg, Germany.
    Printed in the September issue of Thrombosis and Haemostasis.

  • New perspectives, new strategies in venous thromboembolic disease
    A satellite symposium at the 50th ASH Annual Meeting: December 5, 2008 in San Francisco, California, USA.
    Sponsored by an educational grant from Bayer Healthcare AG and Ortho-McNeil Inc., Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc. Administered by Ortho-McNeil Janssen Scientific Affairs, LLC.
    Distributed in association with the June issue of Thrombosis and Haemostasis.
  • Looking for milestone improvements in VWD treatment - tasks defined and resolved
    A symposium at the Hemophilia 2008 World Congress: June 3, 2008 in Istanbul, Turkey.
    Sponsored by Octapharma AG, Switzerland.
    Distributed in association with the March issue of Thrombosis and Haemostasis.

2008

  • The future management of thromboembolic disorders
    Special symposium held during the 54th Annual Scientific and Standardization Committee Meeting of the International Society on Thrombosis and Haemostasis: July 2, 2008 in Vienna, Austria.
    Sponsored by Boehringer Ingelheim.
    Distributed in association with the December issue of Thrombosis and Haemostasis.

  • Symposium: “Von Willibrand disease – a FVIII deficiency? – Selective approach with a dedicated VWF product almost devoid of FVIII”
    A symposium at the XXVIIIth  Hemophilia World Congress, WFH 2008: June 2, 2008 in Istanbul, Turkey.
    Sponsored by LFB.
    Distributedin association with the November issue of Thrombosis and Haemostasis.

  • Von Willebrand factor in factor VIII complex concentrates: From laboratory to clinical practice
    A symposium at the XXVIIIth  Hemophilia World Congress, WFH 2008: June 2, 2008 in Istanbul, Turkey.
    Sponsored by Octapharma AG, Switzerland.
    Distributed in association with the October  issue of Thrombosis and Haemostasis.

  • Coagulation factors – attributes and future direction.
    News from the XXVIII International Congress of the WFH in Istanbul, Turkey, and based on a CSL Behring Symposium.
    Sponsored by CSL Behring GmbH, Marburg, Germany.
    Printed in the September 2008 issue of Thrombosis and Haemostasis.


2007

  • Haemophilia patients with inhibitors – single-dose management with rFVIIa: Minimizing the need for repeated dosing.
    A symposium at the XXIst Congress of the International Society on Thrombosis and Haemostasis (ISTH): July 11, 2007 in Geneva, Switzerland.
    Sponsored by Novo Nordisk, Switzerland.
    Distributed in association with the December issue of Thrombosis and Haemostasis.

  • Haemophilia – VWF in preventing FVIII inhibitors. When science meets clinical experience.
    A symposium at the XXIst Congress of the International Society on Thrombosis and Haemostasis (ISTH): July 11, 2007 in Geneva, Switzerland.
    Sponsored by Octapharma AG, Switzerland.
    Distributed in association with the December issue of Thrombosis and Haemostasis.

  • Plasma therapeutics for preventing and treating bleeding complications.
    News from the XXIst ISTH Congress in Geneva, Switzerland, and based on a CSL Behring Symposium.
    Sponsored by CSL Behring GmbH, Marburg, Germany.
    Printed in the October 2007 issue of Thrombosis and Haemostasis.


2006

  • Educational symposium: “FVIII-neutralizing antibodies – Todays major safety concern for patients with hemophilia A”
    A symposium at the Hemophilia World Congress, WFH 2006: May 24, 2006 in Vancouver, British Columbia, Canada.’
    Sponsored by Octapharma AG, Switzerland.
    Distributed in association with the September issue of Thrombosis and Haemostasis.


2005

  • Actual improvements in the treatment of von Willebrand’s Disease: Wilate – double virus inactivation, high purity and convenience for patients.
    News from the XX ISTH Congress in Sydney, Australia.
    Based on a symposium which took place on August 9th, 2005 at the XX ISTH Congress.
    Symposium as well as this content were sponsored by Octapharma, USA.
    Printed in the November 2005 issue of Thrombosis and Haemostasis.


2004

  • Second International Expert Session on Selective Factor Xa Inhibition. The evolution of thrombosis management: promise, achievements and prospects.
    Content is based on an expert session which took place from September 13-14, 2003, in Prague, The Czech Republic.
    This content as well as the expert session were sponsored by Sanofi-Synthelabo and Organon.
    Distributed in association with the January 2004 issue of Thrombosis and Haemostasis.
  • Direct Thrombin Inhibitors: Heparin-induced Thrombocytopenia and Beyond.
    Content based on a symposium held during the XIX Congress of the International Society on Thrombosis and Haemostasis on the 18th of July, 2003, in Birmingham, United Kingdom.
    This content was sponsored by Mitsubishi Pharma Corporation.
    Distributed in association with the October 2004 issue of Thrombosis and Haemostasis.